A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain

Çukurova University

Status and phase: Completed; Phase 4

Conditions: Chronic Pain

Treatments: Drug: Morphine; Drug: Morphine plus dexmedetomidine

Study type: Interventional

Funder types: Other

Identifiers

NCT02289261

MDICP01

Details and patient eligibility

About

The purpose of this study is to determine whether dexmedetomidine added to morphine is effective in the treatment of chronic cancer pain.

Full description

We conduct the study in Cukurova University Faculty of Medicine Research Hospital after obtaining ethics committee approval and patient's informed consent. Patients with cancer pain are allocated into two group to receive Patient Controlled Analgesia with morphine or morphine plus dexmedetomidine.

Enrollment: 40 patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with chronic cancer pain
• between 20-80 years old age

Exclusion criteria

• the presence of severe systemic disease(cardiac, pulmonary, hepatic or renal)
• psychiatric or neurologic disease
• unable to communicate verbally
• nausea and vomiting
• patient's refusal

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

40 participants in 2 patient groups

Control

Active Comparator group

Description:

Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval

Treatment:

Drug: Morphine

Morphine plus dexmedetomidine

Active Comparator group

Description:

Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval

Treatment:

Drug: Morphine plus dexmedetomidine